Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNX-2401 +/- IFN-gamma in Recurrent Glioblastoma (TARGET-I)
NCT02197169Phase 1Completed
- Sponsor
- DNAtrix
- Start
- Sep 2014
- Primary completion
- Mar 2018
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Ad5-D24RGD in glioblastoma (GBM) and Gliosarcoma (GS) (3 arms), sponsored by DNAtrix. Primary endpoint: Objective Response Rate at 1.5 years. Started Sep 2014; status: completed.
02
Drugs
Ad5-D24RGD
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT02197169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02197169.